ALB and breast cancer: Based on the proved ability of MAL derivative to selectively bind HSA as respect to its non-binding counterpart, e.g., BOC, (Figure 4) we assessed in in vitro cell monolayers obtained from three different breast cancer lines (e.g., human MDA-MB-231, MCF7 and mouse 4T1), if the presence of the albumin-binding moiety on MAL-PTX2S@Pba nanoparticles could effectively enhance their intracellular uptake.